Pharmaceutical Executive
January 23, 2019
Features
39
1
Pharm Exec’s annual look at what lies ahead for the biopharma industry in the coming months examines eight key trends that are seemingly at tipping points in their evolution and poised to shape the life sciences landscape in 2019.
January 21, 2019
Features
39
1
In this Q&A, American-born David Meek, today CEO of Paris-based multinational Ipsen, discusses the drugmaker's bold global expansion and R&D transformation-driven by revamped leadership, a biotech mindset, and promoting external innovation.
January 09, 2019
Columns
39
1
CDER priorities for 2019 include opioids, quality, safety, and innovation.
January 09, 2019
Columns
39
1
Pharma companies are increasingly expanding their portfolios into digital health solutions. To find the right partners, there are several key considerations that inform their evaluation and selection.
January 09, 2019
Features
39
1
Leaders at Novartis share how the big pharma is laying the foundations for a potential new operating model as a "medicines and data science company."
January 01, 2019
Columns
39
1
Being more human in brand engagement doesn’t mean being less transparent
January 01, 2019
Issue PDF
39
1
Click the title above to open the Pharmaceutical January 2019 issue in an interactive PDF format.
January 01, 2019
Special Sponsored Section
39
1
Despite market access hurdles, Turkey’s pharmaceutical market holds tremendous growth potential-in both value and volume. But will the country be able to take that final step in creating a regulatory and economic environment that is conducive to further upward development?
January 01, 2019
From the Editor
39
1
Highlighting a few topics that just missed the cut for our annual Industry Outlook-but are worth keeping a close eye on.